AMANTA HEALTHCARE LIMITED Share price

Amanta Healthcare Limited was originally incorporated on December 21, 1994 as Marck Parenterals (India) Limited with RoC, Gujarat, at Ahmedabad by converting the existing Partnership Firm 'Marck Parenterals (India)' on January 06, 1995. The Company's name was changed to 'Marck Biosciences Limited' on November 2, 2005 and further to 'Amanta Healthcare Limited' w.e.f. June 24, 2014. vide a fresh Certificate of Incorporation issued by the Registrar of Companies, Gujarat. Amanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, packed in plastic container with Aseptic Blow-Fill-Seal (ABFS) and Injection Strech Blow Moulding (ISBM) technology. The Company manufacture large volume parenterals (LVPs) and small volume parenterals (SVPs) in six therapeutic segments. In addition to that, it also manufacturer medical devices. It manufacture fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in medical device segment. The Company introduced Large Volume Parenterals (LVP) project for Formulations, Fluid Therapy & Irrigation Solution in year 1997; and started the L-1 in Block A in 1998. It launched a specialised production line 'LVP Line II' for the manufacture of Large Volume Parenterals in Kheda District of Gujarat in 2002. Further, it launched a specialised production line 'SVP Line I' for the manufacture of Small Volume Parenterals in Kheda, Gujarat in 2005, launched L-III Large Volume Parenterals Facility for 500 ml products in Block -A in 2007; launched a specialised production line 'SVP line II' for the manufacture of Small Volume Parenterals in Gujarat in 2008. Following the approval from National Company Law Tribunal, Ahmedabad, in October 2018, Marck Remedies Private Limited (MRPL) got merged with the Company through the Scheme of Amalgamation and the entire undertaking of MRPL was transferred to the Company as a going concern effective from April 1, 2017. In consideration of the transfer of MRPL's undertaking, 1 fully paid-up Equity Share of Rs 10 of the Company was issued and allotted for every 38 equity shares of Rs 10 each held in MRPL by their respective shareholders. Later on, the Company launched a specialised production line 'SteriPort -Debottlenecking' in 2021 and is currently manufacturing out of seven (7) active production lines including SVP and LVP in 2024. The Company launched the initial public offer by allotting 1,00,00,000 equity shares having the face value of Rs 10 each raising funds of Rs 126 Crore on 3 September, 2025. The Company launched Linezolid I.V. Injection in FY 2025.